Katie Rubino is a Partner in the Corporate Department.

Katie frequently represents clients on target discovery collaborations, assisting in structuring spin-offs, divestitures, and out-licensing from pharma, hospital systems, and academic research institutions. She also counsels life sciences companies developing pharmaceuticals, vaccines, medical devices, antibody products, digital health, and medical devices and advises companies raising growth capital, merger and acquisition transactions, and initial public offerings. Katie is experienced in transactions involving intellectual property rights, strategic partnerships, licensing, and research collaborations.

Katie serves as chair of the Chemistry and the Law division of the American Chemical Society and has been featured in the Wall Street Journal, Fox Business, and Nature Biotechnology.

Katie holds a J.D. from Suffolk University Law School, a Doctor of Pharmacy from Northeastern University, and is dually qualified to practice in both the United States and England and Wales.